Expertise in
21
conditions

Dr. Han W. Tun

Hematology
FL - Cancer
4500 San Pablo Rd S, 
Jacksonville, FL 
Accepting New Patients
Offers Telehealth
Expertise in
21
conditions
FL - Cancer
4500 San Pablo Rd S, 
Jacksonville, FL 

Overview

Han Tun is a Hematologist practicing medicine in Jacksonville, Florida.

Dr. Tun is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Marginal Zone Lymphoma (MZL), Bone Marrow Aspiration, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 121 peer reviewed articles and participating in 9 clinical trials. Dr. Tun is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in FL

Hospital Affiliations

Mayo Clinic

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Sunshine Health
  • EPO
  • HMO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

FL - Cancer
4500 San Pablo Rd S, Jacksonville, FL 32224

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Enrollment Status: Active_not_recruiting
Publish Date: May 15, 2026
Intervention Type: Drug
Study Drugs: LOXO-305, Ibrutinib, Acalabrutinib, Zanubrutinib
Study Phase: Phase 3
Phase I/Ib Study of Parsaclisib (INCB50465), Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (PaR-CHOP) Immunochemotherapy for Patients With Newly Diagnosed High Risk Diffuse Large B-Cell Lymphoma
Phase I/Ib Study of Parsaclisib (INCB50465), Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (PaR-CHOP) Immunochemotherapy for Patients With Newly Diagnosed High Risk Diffuse Large B-Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: February 02, 2026
Intervention Type: Drug, Biological
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Parsaclisib, Pegfilgrastim, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 1
Phase II Expansion Cohorts Studies of a Novel Triple Combination Therapy, DTRM-555, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Non-Hodgkin's Lymphomas
Phase II Expansion Cohorts Studies of a Novel Triple Combination Therapy, DTRM-555, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Non-Hodgkin's Lymphomas
Enrollment Status: Terminated
Publish Date: January 08, 2025
Intervention Type: Drug
Study Drug: Everolimus
Study Phase: Phase 2
A Phase 1 Trial to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
A Phase 1 Trial to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
Enrollment Status: Completed
Publish Date: July 25, 2024
Intervention Type: Drug
Study Drug: Tinostamustine
Study Phase: Phase 1
Phase I/II, Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) With Lenalidomide (R2-ICE) in Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Phase I/II, Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) With Lenalidomide (R2-ICE) in Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment Status: Unknown
Publish Date: July 01, 2024
Intervention Type: Biological, Drug, Other
Study Drugs: Carboplatin, Etoposide, Ifosfamide, Lenalidomide, Rituximab
Study Phase: Phase 1/Phase 2
Phase I Clinical Trial for Evaluation of Nivolumab and Pomalidomide Combination for Relapsed/Refractory Primary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma
Phase I Clinical Trial for Evaluation of Nivolumab and Pomalidomide Combination for Relapsed/Refractory Primary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma
Enrollment Status: Completed
Publish Date: January 06, 2023
Intervention Type: Drug, Biological
Study Drugs: Nivolumab, Pomalidomide
Study Phase: Phase 1
A Phase Ia/Ib Study of a Novel BTK Inhibitor, DTRMWXHS-12, and Combination Products, DTRM-505 and DTRM-555, in Patients With Chronic Lymphocytic Leukemia or Other B-cell Lymphomas
A Phase Ia/Ib Study of a Novel BTK Inhibitor, DTRMWXHS-12, and Combination Products, DTRM-505 and DTRM-555, in Patients With Chronic Lymphocytic Leukemia or Other B-cell Lymphomas
Enrollment Status: Completed
Publish Date: November 27, 2020
Intervention Type: Drug
Study Phase: Phase 1
Phase II Trial of Pentostatin, Cyclophosphamide, and Ofatumumab for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL)
Phase II Trial of Pentostatin, Cyclophosphamide, and Ofatumumab for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL)
Enrollment Status: Completed
Publish Date: September 18, 2018
Intervention Type: Biological, Drug, Other
Study Phase: Phase 2
A Phase 1, Open-label, Dose-escalation Study of SGN-CD19B in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
A Phase 1, Open-label, Dose-escalation Study of SGN-CD19B in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
Enrollment Status: Terminated
Publish Date: August 13, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 8 Less Clinical Trials

121 Total Publications

Dexrazoxane for Cardioprotection During Anthracycline Therapy: A Systematic Review and Meta-Analysis.
Dexrazoxane for Cardioprotection During Anthracycline Therapy: A Systematic Review and Meta-Analysis.
Journal: The Canadian journal of cardiology
Published: May 12, 2026
Similar Doctors
Expertise in
12
conditions
Expertise in
12
conditions
Referral may be required

Mayo Clinic Hospital In Florida

4500 San Pablo Rd S, 
Jacksonville, FL 
 (0.1 miles away)
904-953-2000
Languages Spoken:
English
See accepted insurances

Asher Chanan-Khan is a Hematologist practicing medicine in Jacksonville, Florida. Dr. Chanan-Khan is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma, Waldenstrom Macroglobulinemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
24
conditions
Dr. Vivek K. Roy
Hematology
Expertise in
24
conditions
Dr. Vivek K. Roy
Hematology
Referral may be required

Mayo Clinic Hematology & Oncology

4500 San Pablo Rd S, 
Jacksonville, FL 
 (0.1 miles away)
904-953-7188
Experience:
47+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Vivek Roy is a Hematologist practicing medicine in Jacksonville, Florida. He has been practicing medicine for over 47 years. Dr. Roy is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Waldenstrom Macroglobulinemia, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Roy is currently accepting new patients.

Expertise in
35
conditions
Expertise in
35
conditions
Referral may be required

Mayo Clinic Hematology & Oncology

4500 San Pablo Rd S, 
Jacksonville, FL 
 (0.1 miles away)
904-953-7188
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ernesto Ayala is a Hematologist practicing medicine in Jacksonville, Florida. Dr. Ayala is highly rated in 35 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Graft Versus Host Disease (GvHD), Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Ayala is currently accepting new patients.

Frequently Asked Questions about Dr. Han W. Tun

How do I make an appointment with Dr. Han W. Tun?

You can book an appointment with Dr. Han W. Tun by calling their office at 904-914-7532. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Han W. Tun a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Han W. Tun is classified as an Elite expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Han W. Tun specialize in?

While Dr. Han W. Tun is a Hematology, they have specific expertise in Non-Hodgkin Lymphoma, B-Cell Lymphoma, and Marginal Zone Lymphoma (MZL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Han W. Tun participate in research or clinical trials?

Yes. Dr. Han W. Tun has published 121 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Dr. Han W. Tun's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Han W. Tun accept my insurance?

Dr. Han W. Tun accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 904-914-7532 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tun's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 12 Advanced Conditions
View All 48 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile